**Summary**
British Land Company PLC has announced a recommended cash and share offer for Life Science REIT PLC, a UK Real Estate Investment Trust (REIT) specializing in life science properties. The acquisition, valued at approximately £150 million, will be executed through a court-sanctioned scheme of arrangement under the Companies Act 2006.
**Key Terms of the Offer**
**Consideration** For each Life Science REIT share, shareholders will receive 14.1 pence in cash and 0.07 new British Land shares.
**Valuation** The offer values Life Science REIT shares at approximately 42.8 pence each, representing a 21% premium to the closing price on January 27, 2026, and a 15% premium to the 3-month volume-weighted average price.
**Post-Acquisition Ownership** Life Science REIT shareholders will own approximately 2.4% of the enlarged group, with existing British Land shareholders holding the remaining 97.6%.
**Background and Rationale**
British Land sees this acquisition as an opportunity to
**Enhance its Science & Technology Portfolio:** Life Science REITs assets, located in the "Golden Triangle" (London, Oxford, Cambridge), complement British Lands existing focus on campuses and retail parks.
**Deliver Cost Synergies and Earnings Accretion:** British Land expects to achieve cost savings and immediate earnings per share growth through integrating Life Science REITs portfolio into its platform.
**Target a Broader Range of Occupiers** British Land aims to leverage its platform to attract a wider range of science and technology companies beyond the life sciences sector.
**Benefits for Life Science REIT Shareholders:**
**Increased Diversification** Access to British Lands diversified portfolio, including campuses and retail parks.
**Growth Potential** Exposure to British Lands development pipeline and market-leading operating platform.
**Improved Liquidity** Significantly higher share liquidity compared to Life Science REITs current trading volumes.
**Attractive Dividend** Access to British Lands growing dividend, underpinned by expected earnings growth.
**Recommendation and Next Steps**
The Life Science REIT board, advised by Panmure Liberum, considers the offer fair and reasonable and recommends shareholders vote in favor of the scheme. The acquisition is subject to shareholder approval and court sanction. A scheme document will be sent to shareholders outlining the full terms and conditions.
**Overall, this acquisition represents a strategic move by British Land to expand its presence in the growing science and technology sector while offering Life Science REIT shareholders enhanced diversification, liquidity, and growth potential.**